MYRIAD GENETICS, INC.
NASDAQ: MYGN
▲
26.71
+0.91
+3.53%
1 Day
-
Open
25.52
-
Previous Close
25.80
-
Volume (Avg)
806.74k (995.39k)
-
Day's Range
25.52-27.00
-
52Wk Range
9.24-30.13
-
Market Cap.
1.88B
-
Dividend Rate ( Yield)
-
-
Beta
1.73
-
Shares Outstanding
75.21M
-
P/E Ratio (EPS)
581.41 (-)
Top Stories
-
Myriad Genetics (MYGN), Illumina Partner to Enhance Oncology Arm
Zacks.com 4 days ago -
Myriad Genetics Up on Strategic-Options Plan for Autoimmune Unit
TheStreet -
Stocks making the biggest moves after the bell: Cal-Maine Foods, Myriad Genetics & more
CNBC -
The Daily Biotech Pulse: Aerpio Reviews Strategic Options, Hologic Goes Shopping
Benzinga -
Myriad Genetics Forms Strategic Partnership with Illumina in Oncology
Nasdaq 4 days agoMyriad Genetics, Inc., a leader in genetic testing and precision medicine, today announced a strategic collaboration with Illumina, Inc. for Illumina to create a kit-based version of the myChoice ® companion diagnostic test for international markets.
-
Myriad Genetics (MYGN), Illumina Partner to Enhance Oncology Arm
Nasdaq -
Myriad Genetics Provides Transformation Update, Pursues Strategic Alternatives for Autoimmune Business, Realigns International Operations
Business Insider -
Myriad Genetics Up on Strategic-Options Plan for Autoimmune Unit
TheStreet.com -
Developing Countries To Drive Growth In The Human Genetics Market- Myriad Genetics, QIAGEN, Agilent Technologies, Thermo Fisher Scientific
ARN -
Illumina Announces New and Expanded Oncology Partnerships with Bristol Myers Squibb, Kura Oncology, Myriad Genetics, and Merck to Advance Comprehensive Genomic Profiling
Business Wire -
Myriad Genetics CEO Paul J. Diaz to Present at 39th Annual J.P. Morgan Healthcare Conference
Associated Press -
Stocks making the biggest moves after the bell: Cal-Maine Foods, Myriad Genetics & more
CNBC -
MYGN Jan 2021 50.000 call
Yahoo Finance -
Myriad Genetics Forms Strategic Partnership with Illumina in Oncology
Morningstar%2c Inc. -
Myriad Genetics Provides Transformation Update, Pursues Strategic Alternatives for Autoimmune Business, Realigns International Operations
Morningstar%2c Inc. 1/5/2021SALT LAKE CITY, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the substantial completion of its ...
-
Myriad Genetics CEO Paul J. Diaz to Present at 39th Annual J.P. Morgan Healthcare Conference
Stockhouse -
MYGN Jan 2021 12.000 call
Yahoo Finance -
Myriad Genetics Forms Strategic Partnership with Illumina in Oncology
Business Insider